Ali Ahmadi1, Jennifer M Renaud2, Steven Promislow1, Ian G Burwash1, Girish Dwivedi3, Ran Klein4, Jason G E Zelt1,5, Robert A deKemp2, Rob S Beanlands1,2, Lisa M Mielniczuk6. 1. Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. 2. National Cardiac PET Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada. 3. Harry Perkins Institute of Medical Research, The University of Western Australia, Perth, Australia. 4. Division of Nuclear Medicine, The Ottawa Hospital, Ottawa, ON, Canada. 5. Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 6. Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. lmielniczuk@ottawaheart.ca.
Abstract
BACKGROUND: Reduced left ventricular (LV) function is associated with increased myocardial oxygen consumption rate (MVO2) and altered sympathetic activity, the role of which is not well described in right ventricular (RV) dysfunction. METHODS AND RESULTS: 33 patients with left heart failure were assessed for RV function/size using echocardiography. Positron emission tomography (PET) was used to measure 11C-acetate clearance rate (kmono), 11C-hydroxyephedrine (11C-HED) standardized uptake value (SUV), and retention rate. RV MVO2 was estimated from kmono. 11C-HED SUV and retention indicated sympathetic neuronal function. A composite clinical endpoint was defined as unplanned cardiac hospitalization within 5 years. Patients with (n = 10) or without (n = 23) RV dysfunction were comparable in terms of sex (male: 70.0 vs 69.5%), LV ejection fraction (39.6 ± 9.0 vs 38.6 ± 9.4%), and systemic hypertension (70.0 vs 78.3%). RV dysfunction patients were older (70.9 ± 13.5 vs 59.4 ± 11.5 years; P = .03) and had a higher prevalence of pulmonary hypertension (60.0% vs 13.0%; P = .01). RV dysfunction was associated with increased RV MVO2 (.106 ± .042 vs .068 ± .031 mL/min/g; P = .02) and decreased 11C-HED SUV and retention (6.05 ± .53 vs 7.40 ± 1.39 g/mL (P < .001) and .08 ± .02 vs .11 ± .03 mL/min/g (P < .001), respectively). Patients with an RV MVO2 above the median had a shorter event-free survival (hazard ratio = 5.47; P = .01). Patients who died within the 5-year follow-up period showed a trend (not statistically significant) for higher RV MVO2 (.120 ± .026 vs .074 ± .038 mL/min/g; P = .05). CONCLUSIONS: RV dysfunction is associated with increased oxygen consumption (also characterized by a higher risk for cardiac events) and impaired RV sympathetic function.
BACKGROUND: Reduced left ventricular (LV) function is associated with increased myocardial oxygen consumption rate (MVO2) and altered sympathetic activity, the role of which is not well described in right ventricular (RV) dysfunction. METHODS AND RESULTS: 33 patients with left heart failure were assessed for RV function/size using echocardiography. Positron emission tomography (PET) was used to measure 11C-acetate clearance rate (kmono), 11C-hydroxyephedrine (11C-HED) standardized uptake value (SUV), and retention rate. RV MVO2 was estimated from kmono. 11C-HED SUV and retention indicated sympathetic neuronal function. A composite clinical endpoint was defined as unplanned cardiac hospitalization within 5 years. Patients with (n = 10) or without (n = 23) RV dysfunction were comparable in terms of sex (male: 70.0 vs 69.5%), LV ejection fraction (39.6 ± 9.0 vs 38.6 ± 9.4%), and systemic hypertension (70.0 vs 78.3%). RV dysfunction patients were older (70.9 ± 13.5 vs 59.4 ± 11.5 years; P = .03) and had a higher prevalence of pulmonary hypertension (60.0% vs 13.0%; P = .01). RV dysfunction was associated with increased RV MVO2 (.106 ± .042 vs .068 ± .031 mL/min/g; P = .02) and decreased 11C-HED SUV and retention (6.05 ± .53 vs 7.40 ± 1.39 g/mL (P < .001) and .08 ± .02 vs .11 ± .03 mL/min/g (P < .001), respectively). Patients with an RV MVO2 above the median had a shorter event-free survival (hazard ratio = 5.47; P = .01). Patients who died within the 5-year follow-up period showed a trend (not statistically significant) for higher RV MVO2 (.120 ± .026 vs .074 ± .038 mL/min/g; P = .05). CONCLUSIONS: RV dysfunction is associated with increased oxygen consumption (also characterized by a higher risk for cardiac events) and impaired RV sympathetic function.
Authors: Yeun Ying Wong; Nico Westerhof; Gerrina Ruiter; Mark Lubberink; Pieter Raijmakers; Paul Knaapen; J Tim Marcus; Anco Boonstra; Adriaan A Lammertsma; Willem J van der Laarse; Anton Vonk-Noordegraaf Journal: Eur J Heart Fail Date: 2011-10-20 Impact factor: 15.534
Authors: John J Ryan; Jessica Huston; Shelby Kutty; Nathan D Hatton; Lindsay Bowman; Lian Tian; Julia E Herr; Amer M Johri; Stephen L Archer Journal: Can J Cardiol Date: 2015-01-29 Impact factor: 5.223
Authors: A Gómez; D Bialostozky; A Zajarias; E Santos; A Palomar; M L Martínez; J Sandoval Journal: J Am Coll Cardiol Date: 2001-10 Impact factor: 24.094
Authors: Mark A Peterzan; Craig A Lygate; Stefan Neubauer; Oliver J Rider Journal: Am J Physiol Heart Circ Physiol Date: 2017-06-23 Impact factor: 4.733
Authors: Allison B Hall; Maria C Ziadi; Judith A Leech; Shin-Yee Chen; Ian G Burwash; Jennifer Renaud; Robert A deKemp; Haissam Haddad; Lisa M Mielniczuk; Keiichiro Yoshinaga; Ann Guo; Li Chen; Olga Walter; Linda Garrard; Jean N DaSilva; John S Floras; Rob S B Beanlands Journal: Circulation Date: 2014-07-03 Impact factor: 29.690
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: R S Beanlands; D S Bach; R Raylman; W F Armstrong; V Wilson; M Montieth; C K Moore; E Bates; M Schwaiger Journal: J Am Coll Cardiol Date: 1993-11-01 Impact factor: 24.094
Authors: Yeun Ying Wong; Pieter Raijmakers; Jasmijn van Campen; Willem J van der Laarse; Paul Knaapen; Mark Lubberink; Gerrina Ruiter; Anton Vonk Noordegraaf; Adriaan A Lammertsma Journal: J Nucl Med Date: 2013-06-04 Impact factor: 10.057